» Articles » PMID: 19554203

New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics

Overview
Publisher Informa Healthcare
Specialties Pathology
Radiology
Date 2009 Jun 26
PMID 19554203
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND: The completion of Human Genome Project (HGP) has paved the way for novel, more detailed and accurate molecular diagnostic classification of cancer. With the information from the HGP, cancers can be categorized not only on the morphology or limited immunohistological markers, but according to their "molecular fingerprints" such as gene expression profiles. Technologies detecting these signatures have been developed to simultaneously measure multiple genes or proteins in one assay with high sensitivity and specificity. OBJECTIVE: To evaluate potential innovative novel methods of diagnosis and prognosis in pediatric cancers. METHODS: We selected a variety of promising new diagnostic technologies utilizing molecular signatures which harness the results from HGP including DNA microarray, bead-based detection system, multiplexed RT-PCR, MesoScale Discovery (MSD), and isotope-coded affinity tag (ICAT), as well as their applications in biomarker discovery for pediatric tumors. Label-free detection technologies and the obstacles for taking these new diagnostic technologies from the bench to the bedside are also discussed. CONCLUSION: The use of molecular signatures is gaining acceptance in clinical practice. However, technical challenges need to be addressed before incorporating these new technologies into current diagnostic and prognostic schema.

Citing Articles

Treating metastatic disease: Which survival model is best suited for the clinic?.

Forsberg J, Sjoberg D, Chen Q, Vickers A, Healey J Clin Orthop Relat Res. 2012; 471(3):843-50.

PMID: 22983682 PMC: 3563791. DOI: 10.1007/s11999-012-2577-z.


Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.

Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G Oncotarget. 2011; 1(4):278-288.

PMID: 21304178 PMC: 3248110. DOI: 10.18632/oncotarget.138.

References
1.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

2.
Fritz J, Cooper E, Gaudet S, Sorger P, Manalis S . Electronic detection of DNA by its intrinsic molecular charge. Proc Natl Acad Sci U S A. 2002; 99(22):14142-6. PMC: 137851. DOI: 10.1073/pnas.232276699. View

3.
Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q . Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004; 64(19):6883-91. PMC: 1298184. DOI: 10.1158/0008-5472.CAN-04-0695. View

4.
He L, Thomson J, Hemann M, Hernando-Monge E, Mu D, Goodson S . A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-33. PMC: 4599349. DOI: 10.1038/nature03552. View

5.
Delapeyriere O, Ollendorff V, Planche J, Ott M, Pizette S, Coulier F . Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo. Development. 1993; 118(2):601-11. DOI: 10.1242/dev.118.2.601. View